

# Nicole E Rich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8493358/publications.pdf>

Version: 2024-02-01

74  
papers

3,034  
citations

236925

25  
h-index

175258

52  
g-index

75  
all docs

75  
docs citations

75  
times ranked

3158  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1706-1718.e1.	1.3	695
2	Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 198-210.e2.	4.4	284
3	Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-analysis. <i>Hepatology</i> , 2021, 73, 713-725.	7.3	152
4	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	3.7	139
5	Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 551-559.e1.	4.4	131
6	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1253-1263.e2.	1.3	131
7	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019, 156, 1683-1692.e1.	1.3	121
8	Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. <i>Hepatology</i> , 2020, 72, 1654-1665.	7.3	93
9	Hepatocellular carcinoma tumour markers: Current role and expectations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 843-853.	2.4	89
10	Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 127-137.	3.7	63
11	Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 242-248.e5.	4.4	57
12	Malignant Infiltration of the Liver Presenting as Acute Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1025-1028.	4.4	56
13	Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1561-1569.e4.	4.4	52
14	Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. <i>Gut</i> , 2021, 70, gutjnl-2020-321040.	12.1	48
15	Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 701-709.	3.7	45
16	The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1531-1541.	6.3	43
17	Medical Management of Hepatocellular Carcinoma. <i>Journal of Oncology Practice</i> , 2017, 13, 356-364.	2.5	42
18	Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3428-3436.	4.1	41

#	ARTICLE	IF	CITATIONS
19	Comparative Analysis of Nonalcoholic Steatohepatitis Versus Viral Hepatitis and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 322-329.	4.9	38
20	Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 683-690.	3.7	38
21	Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1063-1071.	4.9	32
22	Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e267-e288.	4.4	32
23	Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 296-304.	0.8	29
24	Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. <i>Seminars in Liver Disease</i> , 2017, 37, 296-304.	3.6	29
25	Evaluation of a Multifaceted Intervention to Reduce Health Disparities in Hepatitis C Screening: A Pre-Post Analysis. <i>Hepatology</i> , 2019, 70, 40-50.	7.3	29
26	Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. <i>Hepatology Communications</i> , 2021, 5, 1481-1489.	4.3	28
27	Racial and Sex Disparities in Hepatocellular Carcinoma in the USA. <i>Current Hepatology Reports</i> , 2020, 19, 462-469.	0.9	26
28	State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. <i>Hepatology</i> , 2021, 74, 1384-1394.	7.3	26
29	Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?. <i>Hepatology</i> , 2022, 75, 740-753.	7.3	26
30	Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2818-2825.e1.	4.4	26
31	Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. <i>Cancer Prevention Research</i> , 2021, 14, 955-962.	1.5	22
32	Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 670-680.e18.	4.4	22
33	Racial and Ethnic Disparities in Barriers to Care in Patients with Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1094-1096.e2.	4.4	22
34	Reconstructive options for the medial canthus and eyelids following tumor excision. <i>Saudi Journal of Ophthalmology</i> , 2011, 25, 67-74.	0.3	21
35	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2522-2534.	3.9	20
36	Comparison of Postoperative Eyelid Position Using Fibrin Sealant versus Suture for Wound Closure in Malar Muscles Conjunctiva Resection Ptosis Repair. <i>Plastic and Reconstructive Surgery</i> , 2011, 128, 423-430.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. <i>Hepatoma Research</i> , 2020, 2020, .	1.5	19
38	Racial, Ethnic, and Socioeconomic Disparities in Curative Treatment Receipt and Survival in Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1186-1197.	4.3	19
39	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	1.3	17
40	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 974-983.	4.4	16
41	Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient-Derived Xenograft Assays. <i>Hepatology</i> , 2020, 72, 1085-1101.	7.3	16
42	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	4.4	15
43	Patient and provider-level barriers to hepatitis C screening and linkage to care: A mixed-methods evaluation. <i>Journal of Viral Hepatitis</i> , 2020, 27, 680-689.	2.0	15
44	Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1091-1093.e3.	4.4	15
45	Harms of Hepatocellular Carcinoma Surveillance. <i>Current Hepatology Reports</i> , 2019, 18, 383-389.	0.9	14
46	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1157-e1169.	4.4	12
47	Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 422-424.	8.1	11
48	Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. <i>Transplantation Direct</i> , 2022, 8, e1313.	1.6	10
49	“Raising HOPE”: Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. <i>Transplantation Direct</i> , 2021, 7, e707.	1.6	9
50	High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	2.3	8
51	Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. <i>Hepatology Communications</i> , 2022, 6, 223-236.	4.3	8
52	Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. <i>American Journal of Gastroenterology</i> , 2021, 116, 976-983.	0.4	8
53	Gender, Age, Racial and Ethnic Disparities in Clinical Trial Enrollment for Primary Liver Cancer. <i>Gastroenterology</i> , 2022, 163, 14-20.e2.	1.3	7
54	Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 988-994.e2.	4.4	7

#	ARTICLE	IF	CITATIONS
55	Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma. Transplantation, 2017, 101, e12-e19.	1.0	5
56	Pro: Liver Transplantation Should Be Considered in Select Patients With Acute Alcoholic Hepatitis. Clinical Liver Disease, 2019, 13, 140-143.	2.1	5
57	Hepatocellular Carcinoma Surveillance and Staging. Molecular and Translational Medicine, 2019, , 27-51.	0.4	5
58	Systematic review with meta-analysis: incidence of variceal hemorrhage in patients with cirrhosis undergoing transesophageal echocardiography. Alimentary Pharmacology and Therapeutics, 2022, 55, 1088-1098.	3.7	5
59	Direct-Acting Antiviral Therapy and Hepatocellular Carcinoma. Clinical Liver Disease, 2021, 17, 414-417.	2.1	4
60	DETECT: Development of Technologies for Early HCC Detection. Gastroenterology, 2022, 163, 21-27.	1.3	4
61	Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Potential New Challenge for Hepatocellular Carcinoma Surveillance. Gastroenterology, 2016, 151, 1246-1248.	1.3	3
62	Correlation of LI-RADS 3 or 4 Observations with Histopathologic Diagnosis in Patients with Cirrhosis. Clinical Gastroenterology and Hepatology, 2023, 21, 1351-1353.e2.	4.4	3
63	LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. Abdominal Radiology, 2021, 46, 3708-3716.	2.1	2
64	The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon With Acceptable Outcomes. Transplantation Direct, 2022, 8, e1297.	1.6	2
65	CON (The window is closed): In patients with cirrhosis with ascites, the clinical risks of nonselective beta-blocker outweigh the benefits and should NOT be prescribed. Clinical Liver Disease, 2018, 11, 123-127.	2.1	1
66	16 RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA IN PATIENTS WITH INDETERMINATE (LI-RADS 3) OBSERVATIONS. Gastroenterology, 2021, 160, S-759-S-760.	1.3	1
67	S1191 Trajectory of Cancer-Associated Weight Loss in Patients With Hepatocellular Carcinoma Is Associated With Prognosis. American Journal of Gastroenterology, 2021, 116, S553-S554.	0.4	1
68	2207. Barriers to HCV Treatment in a Safety-Net Hospital System. Open Forum Infectious Diseases, 2018, 5, S651-S652.	0.9	0
69	Reply. Gastroenterology, 2018, 155, 1275-1276.	1.3	0
70	Editorial: liver test abnormalities in oncology patients in the age of the checkpoint inhibitors. Alimentary Pharmacology and Therapeutics, 2019, 50, 831-832.	3.7	0
71	REPLY:. Hepatology, 2021, 73, 2618-2619.	7.3	0
72	REPLY:. Hepatology, 2021, 74, 1715-1715.	7.3	0

#	ARTICLE	IF	CITATIONS
73	REPLY: “Look for a physical health status surrogate in hepatocellular carcinoma: Have we found the holy grail?” Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
74	Comparable survival for hepatitis C-related hepatocellular carcinoma after liver transplantation irrespective of viremic status. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0